Jan Hartmann: New Transformative Treatment for Hemophilia A
Jan Hartmann, Senior Vice President, Chief Medical Officer at Haemonetics, shared a post on LinkedIn:
”Congratulations to the team led by Kunihiro Hattori, Takehisa Kitazawa, and Tomoyuki Igawa of Chugai Pharmaceutical Co., Ltd. on being awarded the 2026 Lasker-DeBakey Clinical Medical Research Award for their pioneering development of a bispecific antibody that revolutionized the treatment of Hemophilia.
First approved in 2017 and subsequently licensed by Genentech, emicizumab (Hemlibra) provided a transformative new treatment option for people living with hemophilia A.
Beyond its impact on patient care, its success demonstrated the potential of bispecific antibodies as a therapeutic platform and helped catalyze the development of this modality across a wide range of diseases.”
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 10, 2026, 05:09Shelby Bradford: Award-Winning Science Incoming
-
Sep 9, 2026, 17:57CRISPR/Cas Gene Editing in β-Thalassemia: From Molecular Correction to Clinical Reality
-
Sep 9, 2026, 17:38Cardiovascular Health in Bleeding Disorders – EHC
-
Sep 9, 2026, 17:33Manasvi Shah: Co-Inheritance of Alpha Globin Gene Multiplication With Beta Globin Gene Abnormalities
-
Sep 9, 2026, 17:29Christina Crossette-Thambiah: One of the Largest Studies to Date in Antiphospholipid Syndrome
-
Sep 9, 2026, 17:25Alan Nurden: A miR-146a Variant Reveals a New Pathway Linking Platelet Metabolism and Thrombosis
-
Sep 9, 2026, 17:17When Is Thrombophilia Testing Appropriate and How Can the Evidence Guide Clinical Care? – ISTH
-
Sep 9, 2026, 16:07Zahra Safarzadeh: From Novel F8 Variant to Clinical Significance
-
Sep 9, 2026, 16:00Maximo Agustin Schiavone: HDL Beyond Cholesterol – Linking Lipids and Immunity